Insider

Royalty Pharma plc

RPRX Health Care · No analyses yet

Mentioned in recent filings: Ukraine Russia Tariffs

What changed

No articles about this company yet. Follow it to hear when the first one appears.

Sector peers

How this company compares with 36 covered companies in Health Care (median revenue change +7.2% YoY), from archived SEC XBRL filings.

CompanyLatest revenueRevenue YoYOperating margin
Royalty Pharma plc RPRX———
Unitedhealth Group Inc UNH$113B-0.4%5.8%
Mckesson Corp MCK$111B+7.6%1.4%
CVS Health Corp CVS$108B+5.4%3.3%
Cigna Group CI$73.7B+5.6%3.3%
Cardinal Health Inc CAH$67.5B+5.5%1.1%
Elevance Health, Inc. ELV$51.4B+1.4%2.5%

Latest reported period per company from SEC CompanyFacts (XBRL). Fiscal calendars differ across companies.

Large funds (13F)

FundSharesValueChange in sharesQuarter
BlackRock27,832,977$1,560,595,060+7.4%Q2 2026
Fidelity (FMR)24,513,814$1,374,489,542-2.5%Q2 2026
State Street12,338,229$691,804,500+12.3%Q2 2026
Geode Capital Management8,058,048$450,581,226+2.4%Q2 2026
Norges Bank (Norway's sovereign fund)5,336,084$299,194,230—Q2 2026
Two Sigma Investments2,920,163$163,733,539+29.7%Q2 2026
Renaissance Technologies1,935,800$108,540,306+144.7%Q2 2026
Citadel Advisors1,354,640$75,954,665-49.5%Q2 2026
D. E. Shaw & Co.525,114$29,443,142-53.2%Q2 2026
Bridgewater Associates219,687$12,317,850—Q2 2026
Millennium Management12,043$675,251—Q2 2026
T. Rowe Price11,193,657$627,629+478.7%Q2 2026
Wellington Management7,105$398,377-0.4%Q2 2026

From the quarterly 13F-HR holdings reports of the large funds we follow, as filed. Funds file up to 45 days after the quarter ends, so positions may have changed since. Change: against the same fund's previous quarter. Not a recommendation.